Claudia Iannone
Country: Italy
Claudia is a Rheumatology resident at Milan University, carrying out her research at Gaetano-Pini Hospital in Milan, Italy. Her research interests are focused systemic sclerosis, interstital lung disease in rheumatic diseases and vasculitis.She is a member of the Italian Society of Rheumatology of EULAR lung study group and of EUSTAR YIG.
Claudia is part of the social media subcommittee
E-mail: claudia.iannone@unimi.it
| Poster 0317 | Friday 13.06.25 09:30 AM Clinical Poster Tours: Systemic lupus erythematosus II Author: Andrea Fava (USA) Title: The immune map of lupus nephritis: a spatially-resolved kidney proteomic approach  This study developed an innovative 18-plex serial immunohistochemistry workflow to map the spatial organization of immune cells in lupus nephritis kidney biopsies. Using advanced AI-assisted analysis on 29 kidney biopsies containing nearly 2 million cells, researchers identified over 12,000 cellular aggregates and discovered distinct immune cell structures in different kidney regions.The findings revealed that while most aggregates were small, medium and large aggregates contained one-third of all immune cells and showed different compositions related to disease severity. Glomerular aggregates were primarily composed of myeloid cells and associated with protein levels, while tubulointerstitial aggregates showed greater diversity and correlated with kidney function. This spatial mapping approach provides new insights into lupus nephritis pathogenesis and potential therapeutic targets. |
| Oral 0202 | Thursday 12.06.2025 11:10 AM Clinical Abstract Sessions: New hot stuff in Lupus treatment Author: Saira Sheikh (USA) Title: RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis This Phase 1/2 clinical trial evaluates rese-cel, an innovative CAR T cell therapy designed to “reset” the immune system in SLE patients. Six patients received a single weight-based infusion following preconditioning, with excellent safety profiles and remarkable early results. All patients achieved clinical improvement within 1-9 months of follow-up, with three non-renal SLE patients reaching LLDAS and DORIS remission by week 4-8. Both lupus nephritis patients showed significant reductions in proteinuria, with one achieving complete renal response. Importantly, all patients remain off immunosuppressive therapy and have successfully tapered corticosteroids, suggesting the potential for durable drug-free remission through immune system reset. |
| Poster 0325 | Friday 13.06.2025 10:00 AM Clinical Poster Tours: Systemic lupus erythematosus II Author: Junaid Patel (UK) Title: Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment This 20-year observational study identified “rituximab super-responders”: SLE patients with sustained remission lasting more than 3 years after a single cycle of treatment. Among 114 patients, 20% achieved super-response with median duration of 263 weeks, and remarkably, 35% of these maintained drug-free remission without any immunosuppressants. Super-response was associated with non-European ancestry, concurrent antiphospholipid syndrome, and early disease duration, along with sustained suppression of plasmablast repopulation. These findings suggest that sustained drug-free remission is achievable with rituximab and related to the overall immune environment rather than the specific B-cell killing method, supporting early use of anti-CD20 antibodies in poor-prognosis SLE patients. |
| Oral 0272 | Friday 13.06.2025 11:00 AM Basic and Clinical Abstract Sessions: Antiphospholipid Syndrome Author: Pedro Gaspar (Portugal) Title: Antiphospholipid Antibodies Negativization is Associated with Decreased Risk of Recurrent Thrombosis in Thrombotic Primary Antiphospholipid Syndrome This retrospective cohort study of 71 patients with thrombotic primary antiphospholipid syndrome investigated the clinical impact of antiphospholipid antibody negativization over 7.7 years of follow-up. Remarkably, 35% of patients became negative for all antiphospholipid antibodies during follow-up. The study’s key finding shows that while antibody negativization doesn’t affect thrombosis risk before it occurs, it dramatically reduces recurrent thrombosis risk by 85% after negativization. Patients with lupus anticoagulant, anti-β2-glycoprotein I antibodies, or triple positivity were less likely to become antibody-negative. These results suggest that serial monitoring of antiphospholipid antibodies could be valuable in clinical practice, as negativization may indicate reduced thrombotic risk and potentially guide treatment decisions. |
| Oral 0272 | Friday 13.06.2025 15:15 PM Basic and Clinical Poster Tours: Antiphospholipid syndrome Author: Jun Li (China) Title: Three distinct clinical subgroups of antiphospholipid antibodies-associated thrombocytopenia with different prognosis: a prospective cohort study with cluster analysis This prospective cohort study used cluster analysis to identify three distinct clinical subgroups among 123 patients with antiphospholipid antibodies-associated thrombocytopenia from the CAPSTONE cohort. Cluster 1 (28.4%) consisted mainly of men with high cardiovascular risk factors and atherothrombotic events. Cluster 2 (41.5%) included only females characterized by pregnancy morbidity and mild anaemia with high risk of recurrent pregnancy complications. Cluster 3 (30.1%) presented with isolated severe thrombocytopenia but had the best event-free survival. The study demonstrates that platelet count alone cannot assess outcomes in isolated thrombocytopenia patients, and different clinical subtypes require tailored treatment approaches – with males needing enhanced cardiovascular risk management and females with pregnancy history requiring closer anticoagulation monitoring during pregnancies. |